Drotaverinum-teva 40mg tab 20 pc

Description

Composition
Active substance:
1 tablet contains: drotaverine hydrochloride 40.00 mg ;.
Excipients:
Lactose monohydrate 67.00 mg; povidone K25 4.00 mg; microcrystalline cellulose 21.00 mg; croscarmellose sodium 5.00 mg; magnesium stearate 3.00 mg.
Description:
Round flat tablet with beveled, yellow with a greenish tinge. The ability to easily “marbling”.
Product form:
Tablets of 40 mg. 20 tablets in blister Al / PVC. 1,2 or 3 in the blister cardboard pack together with instructions for use.
Contraindications
Hypersensitivity to drotaverine or to any component of the drug; severe renal insufficiency; severe liver failure (class C Child-Pugh); severe heart failure (low cardiac output syndrome); Children under 6 years of age; breastfeeding; lactose intolerance, lactase deficiency, a syndrome of glucose-galactose malabsorption.
Carefully
Pregnancy, hypotension, simultaneous application of L-dopa.
Dosage
40 mg
Indications
Smooth muscle spasms associated with diseases of the liver and biliary tract: cholelithiasis, cholecystitis, pericholecystitis, cholangitis, papillitis; spasms of smooth muscles of the urinary system: urolithiasis, pyelitis, cystitis, bladder tenesmus.
As an adjuvant therapy: gastrointestinal spasms of smooth muscle: gastric ulcer and duodenal ulcer, gastritis, gastric cardia and pyloric spasm, enteritis, colitis accompanied by constipation and flatulence; tensor headache; dysmenorrhea.
Interaction with other drugs
With simultaneous use of drotaverine may reduce the antiparkinsonian effect of levodopa.
While the use of papaverine, bendazol may increase antispasmodic action.
Overdose
Data on drug overdose Drotaverinum Teva-no.
Symptoms of overdose can be heart arrhythmias and conduction disorders (including complete bundle branch block), heart failure, including death.
Treatment: gastric lavage, symptomatic therapy.
pharmachologic effect
Pharmacological group:
Antispasmodic.
Pharmacodynamics:
Drotaverine – isoquinoline derivative which exerts a spasmolytic effect on smooth muscle by inhibiting the enzyme phosphodiesterase 4 (PDE4). Inhibition of PDE-4 enzyme leads to increased concentrations of cyclic AMP (cAMP), which inactivates the myosin light chain kinase (MLCK), which in turn leads to smooth muscle relaxation.
Drotaverine inhibit PDE4 in vitro enzyme without inhibiting isoenzymes PDE-3 and PDE-5. Apparently, PDE4 functionally very important to reduce the contractility of smooth muscle, however, selective PDE4 inhibitors may be effective in the treatment of hyperkinetic disorders and diseases associated with spastic conditions of the gastrointestinal tract (GIT). The enzyme hydrolyzes cAMP in myocardial cells, smooth muscle and blood vessels, is essentially isoenzyme PDE 3, which explains the high efficiency as a spasmolytic drotaverine expressed in the absence of action on the cardiovascular system and serious cardiovascular side effects. Drotaverine effective spasm of smooth muscle as neural and muscle etiology. Regardless of the type of the autonomic innervation of drotaverin acts on smooth muscles of the gastrointestinal tract, biliary tract, and the genitourinary and vascular systems. Thanks to the vasodilator action Drotaverinum improves blood circulation.
Pharmacokinetics:
Absorption and distribution
The oral and parenteral administration Drotaverinum rapidly and completely absorbed.
Maximum plasma concentration (Cmax) is achieved within 45-60 minutes. Bound to plasma proteins (albumin, alpha, alpha- and beta-globulin).
Metabolism and excretion
It is metabolized in the liver. The half-life (T1 / 2) – 16-22 hours After 72 hours drotaverin excreted mainly as metabolites -pochkami 50%, 30% -. Through the intestine.
Pregnancy and breast-feeding
Drotaverine does not possess teratogenic and embryotoxic effect. However, the use of the drug-Drotaverine Teva recommended only after careful consideration and use ratio assumed possible risk.
Due to the lack of clinical data product Drotaverinum-Teva is not recommended during breast-feeding.
Conditions of supply of pharmacies
Without recipe.
side effects
Side effects classified in accordance with the following frequency: very often – at least 10%; often – at least 1% but less than 10%; infrequently – at least 0.1% but less than 1%; rarely – at least 0.01% but less than 0.1%; very rare (including individual messages) – less than 0.01%; frequency is unknown – the data is insufficient to estimate the frequency of the phenomenon in the population.
On the part of the digestive tract: rarely – nausea, constipation.
Central nervous system: rarely – headache, dizziness, and insomnia.
With the cardiovascular system: rarely – palpitations; very rarely – lowering blood pressure.
special instructions
In applying the drug-Drotaverinum Teva in patients with arterial hypertension with caution. The composition includes lactose tablets, and the drug-Teva Drotaverine not prescribed to patients with lactose intolerance, lactase deficiency, syndrome glucose-galactose malabsorption.
Effects on ability to transport management and work with the technique:
When administered in therapeutic doses, the drug-Drotaverinum Teva has no influence on the ability to engage in potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
Store at a temperature not higher than 25 C.
Keep out of the reach of children!.
Dosing and Administration
Inside, drinking plenty of fluids.
The recommended daily adult dose is 120-240 mg (2-3 doses).
Children aged 6 to 12 years with a maximum daily dose of 80 mg, divided in 2 doses; for children older than 12 years, the maximum daily dose is 160 mg, divided into 2-4 doses.
The recommended duration of treatment without consulting a doctor 1-2 days.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist